Rein therapeutics reports first quarter 2025 financial results and provides business update

Renew phase 2 trial evaluating the safety, tolerability, and efficacy of lti-03 in idiopathic pulmonary fibrosis (ipf) initiated with topline interim data expected in the first half of 2026 two abstracts accepted to the american thoracic society (ats) 2025 international conference cash runway extended following previously announced warrant transactions and private placement austin, texas , may 15, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended march 31, 2025 and provided a business update. "rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the phase 2 renew trial of lti-03 in patients with ipf," said brian windsor, ph.d.
RNTX Ratings Summary
RNTX Quant Ranking